HCW Biologics (HCWB) Q4 2024 earnings summary

Executive summary

• Reported financial and business results for Q4 and fiscal year ended December 31, 2024, highlighting progress in immunotherapy pipeline and new drug discovery platforms.

• Received FDA clearance to initiate Phase 1 trial for HCW9302 in alopecia areata and advanced preclinical TRBC platform for immune-cell engagers.

• Entered exclusive worldwide licensing agreement for HCW11-006 with WY Biotech, with $7.0 million expected in June 2025.

• Raised $16.3 million in 2024 through private placements, senior notes, and securities purchase agreements; established equity purchase agreement for up to $20 million over 36 months.

• Substantial doubt exists regarding ability to continue as a going concern without additional funding.

Financial highlights

• Q4 2024 revenue was $394,000, down from $1.3 million in Q4 2023; full-year 2024 revenue was $2.6 million, down from $2.8 million in 2023.

• Q4 2024 net loss was $3.4 million, improved from $10.7 million in Q4 2023; full-year 2024 net loss was $30.0 million, up from $25.0 million in 2023, mainly due to increased legal expenses.

• R&D expenses decreased 51% year-over-year in Q4 and 17% for the full year, reflecting fewer ongoing clinical trials.

• Legal expenses surged 142% year-over-year to $15.9 million in 2024, primarily due to arbitration with ImmunityBio.

• Recognized a $1.3 million loss in 2024 from misdirected funds due to fraud.

Outlook and guidance

• Ongoing financing plan includes additional capital-raising activities in H1 2025; failure to secure funding may require cost reductions and business plan revisions.

• Substantial doubt remains about ability to continue as a going concern for at least 12 months from the financial statement issuance date.